⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 31, 2012Journal of Clinical OncologyOpen Access

Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia

Alan K. Burnett Nigel H. Russell Robert K. Hills Jonathan Kell Sylvie Freeman Lars Kjeldsen Ann E. Hunter John Yin Charles Craddock Inge Høgh Dufva Keith Wheatley Donald Milligan

View Full Paper

Ask AI

Bookmark

Share

Abstract

Adding GO (3 mg/m(2)) to induction chemotherapy reduces relapse risk and improves survival with little increase in toxicity.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Burnett et al. (2012) studied this question.

synapsesocial.com/papers/69d95427e6ab964fb0835a4a https://doi.org/10.1200/jco.2012.42.2964

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Therapeutic Advances in Acute Myeloid LeukemiaOriginal Research · 2011 · 787 citations
2Age and acute myeloid leukemiaPrognostic Study · 2006 · 1,353 citations
3A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicityEarly-Phase Clinical Trial · 1994 · 181 citations
4Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid LeukemiaLate-Phase Clinical Trial · 2005 · 249 citations
5An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of LinkerOriginal Research · 2001 · 230 citations

More related papers

Efficacy and Safety of Gemtuzumab Ozogamicin in Patients With CD33-Positive Acute Myeloid Leukemia in First Relapse2001
Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33‐positive acute myeloid leukemia in first recurrence2005
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial2010

More from Journal of Clinical Oncology

Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast CancerTue,
Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III TrialMon,